Brean Capital downgraded it...hahahahahaha
to decipher the psycho-babble in the last paragraph?
Sure, they have tried to convey, in a statement as long as possible, as not to omit anything that is vague and not meaningful, and not relegate it to another statement as to prejudge it as less important, that they are downgrading CLSN because they don't know if "sustainability of a positive valuation inflection upon the potential showing of a progression free survival (PFS) benefit due to the need to show at least a clinically meaningful overall survival (OS) benefit thereafter, which after only a single administration of one active therapy (RFA) versus two active therapies (RFA and ThermoDox), appears more difficult than benefiting PFS, given the introduction of any additional therapy between progression and death" so therefore to further clarify I'd say that there are many unknowns, and world is very unpredictable, and since they don't know, they therefor conclude that if they did know, they would perhaps be more specific, but as it is they don't know if.... ((sorry to cut this short... :-))
WTF ?
GO CLSN !